The most recent genome-wide association study in amyotrophic lateral sclerosis (ALS) demonstrates a disproportionate contribution from low-frequency variants to genetic susceptibility of disease. We have therefore begun Project MinE, an international collaboration that seeks to analyse whole-genome sequence data of at least 15,000 ALS patients and 7,500 controls. Here, we report on the design of Project MinE and pilot analyses of newly whole-genome sequenced 1,264 ALS patients and 611 controls drawn from the Netherlands. As has become characteristic of sequencing studies, we find an abundance of rare genetic variation (minor allele frequency < 0.1%), the vast majority of which is absent in public data sets. Principal component analysis reveals local geographical clustering of these variants within The Netherlands. We use the whole-genome sequence data to explore the implications of poor geographical matching of cases and controls in a sequencebased disease study and to investigate how ancestry-matched, externally sequenced controls can induce false positive associations. Also, we have publicly released genome-wide minor allele counts in cases and controls, as well as results from genic burden tests.
Introduction
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing, fatal neurodegenerative disease. 1 Twin studies estimate the heritability of ALS to be ~60%, suggesting a strong genetic component contributing to disease risk, 2 and approximately 10-15% of patients have a clear family history of disease. 3 Genetic risk factors have been extensively studied in familial ALS cases, and this effort has led to the identification of highly penetrant causal mutations, including mutations residing in SOD1, 4 TARBP, 5 FUS, 6 and C9orf72. 7, 8 In so-called sporadic ALS cases, who have no known family history of disease and comprise the majority of all cases, only a small number of other common genetic risk loci have been identified. Among these loci are the ATXN2 CAG repeat expansion, 9 mutations in C21orf2, 10 common variation within the UNC13A, 11 SARM1, 12 MOBP, 10 and SCFD1 10 loci and, most importantly, the highly pathogenic C9orf72 repeat expansion. The latter highlights the typical categorization of "familial" and "sporadic" ALS as likely non-distinct groups with overlapping genetic architectures.
Despite these recent advances in ALS genetics, the bulk of risk loci in ALS remain undiscovered. The most recent and largest ALS GWAS, performed in 12,577 cases and 23,475 controls, showed a disproportionate contribution of low-frequency variants to the overall risk of ALS. 10 Genome-wide association studies to date have focused almost exclusively on common variation (minor allele frequency > 1%), leaving lower-frequency and rarer variants segregating in the general population essentially untested. Thus, there is a pressing need to study rare variation across the full length of the genome in cases with and without family history of disease. To this end, we have begun Project MinE, a large-scale whole-genome sequencing study in ALS. The project leverages international collaboration and recent developments in sequencing technologies, allowing us to explore the full spectrum of genetic variation in samples collected worldwide. Project MinE seeks to obtain sequencing data in 15,000 ALS patients and 7,500 matched controls with the aim of identifying new loci associated to ALS risk, fine-map known and novel loci, and provide the ALS community (and the disease research community at large) with a publicly-available summary-level dataset that will enable further genetic research of this and other diseases. A data access committee controls access to raw data, ensuring a FAIR data setup (http://www.datafairport.org).
While common variant association studies have become mostly standardized over the last decade, rare variant association studies such as Project MinE face an array of new challenges. Sequencing studies demand large sample sizes to detect small effects at rare variants, thus making large-scale collaborative consortia a necessity.
Sequence data itself, measuring into the terabytes, poses a substantive data storage, processing, and management challenge. The analytic effects of (tight) 15 and statistical analysis of the data. Here, we discuss the "pilot phase" of Project MinE, performed in 1,264 cases and 611 controls collected in the Netherlands. Though the sample size is too small to detect moderate-effect genetic associations, it allows us to explore the implications of these many analytic challenges faced by Project MinE or any disease study employing sequence data, to understand the genetic basis of disease. We outline the formation of the consortium, study design challenges, data quality control and analysis approaches employed by the project, and publicly release all minor allele counts in cases and controls together with results from genic burden tests derived from this dataset.
Material and methods

Consortium design
The MinE consortium includes ALS research groups from 16 different countries collaborating in a "franchise" design (www.projectmine.com, Figure 1 ). This design means that samples and sample-affiliated data (e.g., dense phenotyping) from partners are collected, processed and stored according to the same protocol, while partners maintain full control over their samples, affiliated data, and any additional data generated on those samples. Within the consortium, ALS patients and controls are ascertained through clinics affiliated to the research groups. At these clinics, neurologists obtain a standardized core clinical data set with phenotypic information (Supplementary Table 1 ) and blood is drawn for DNA isolation. DNA samples are stored on site, but are collectively prepared for sequencing at commercial sequencing providers, in batches of up to 1,000 samples. The consortium continues to expand, welcoming research groups who wish to dedicate time and raise money to understand the genetic and environmental underpinnings of ALS.
A number of variables, including pricing for varying numbers of genomes, DNA input requirements, availability of PCR-free library preparation, and methods for data delivery, were all considered during selection of a sequencing provider (Supplementary Table 2 ). The majority of the data to date have been sequenced at Illumina (San Diego, CA, USA); a small subset is currently being sequenced locally in Australia and Canada. From Illumina, the data are transferred through the internet (via a secure connection) to SURFsara (Amsterdam, The Netherlands). After arrival, the data is automatically checked for corruption and stored in duplicate on two geographically separated tape silos. The storage system is connected to a distributed parallel file system (dCache 16 ) that provides high performing file service to to the consortium and then gain access to all genomes and make use of the SURFsara compute facilities (Figure 1) . Access to the data or usage of the compute facilities is contingent on (a) X.509 authentication certificates and (b) proposed analyses for the data. This data infrastructure allows, for example, particular cohorts and individuals access to particular subsets or all of the data, depending on the analysis. Based on permission given by the manager of the data (i.e., the principal investigator of the contributing research group), access is provided through the gridftp protocol v2 that is tailored for large and reliable file transfers. The X.509
certificates allow for the possibility to scale out to other compute facilities; given valid credentials, the data can then be accessed from anywhere.
Sample selection
Patients were diagnosed with definite, probable, and probable lab-supported ALS according to the revised El Escorial Criteria. 17 For the pilot analyses presented here, all patients were seen by neurologists specialized in motor neuron diseases at the University Medical Center Utrecht and Academic Medical Center (Amsterdam, The Netherlands). The samples were all included in the Prospective ALS study in the Netherlands (PAN), an incidence-based registry of ALS cases 18 . Controls were population-based controls that were matched for age, sex, and geographical region.
As is true for all contributing cohorts to Project MinE, cases and controls were ascertained in a roughly 2:1 ratio; the 2:1 case-control ratio was selected to improve detection of variants in cases and with the plan to include publicly-available sequenced controls in future analyses.
Phenotypic information
For all participants in Project MinE, we have defined a core clinical dataset, meant to be collected and made available for all cases (Supplementary Table 1 ). Phenotypic information is stored physically separately (https://euromotor.umcutrecht.nl) from the genetic data in a clinical database called Progeny. The phenotypic and genetic data can be connected through sample identifiers. Phenotypic data storage is organized similarly to the sequencing data: every contributing group has default full access to their own phenotypic data, but data can easily be jointly shared analysed if desired. Table 1 
This core clinical dataset (Supplementary
Whole-genome sequencing
Venous blood was drawn from patients and controls from which genomic DNA was isolated using standard methods. We set the DNA concentrations at 100ng/ul as measured by a fluorometer with the PicoGreen® dsDNA quantitation assay. DNA integrity was assessed using gel electrophoresis. All samples were sequenced using Principal component analysis. Principal components were calculated for all individuals including variants at different allele frequency thresholds using GCTA. 21 The eigenvectors of the first twenty principal components were regressed on latitude and longitude of birthplace. In a leave-one-out scheme, this linear model was used to predict the birthplace for the individual left out.
Identity-by-descent analysis.
We phased all non-singleton variants using SHAPEIT2 22 and then used BEAGLE4 23 to detect runs of identity-by-descent (IBD) between individuals.
Association analysis. Genotypes at common variants (MAF > 0.5%) were tested for an association with case/control status using logistic regression (PLINK v1.9) 24,25 assuming an additive model. Optionally, the first 10 principal components (PCs) were included as covariates. To test rare variation, we performed genic "burden" testing. All variants were functionally annotated using ANNOVAR 26 . We then determined three functional groups for gene-based association testing: (a) loss of function (LOF) mutations (premature stop mutations, stop-loss mutations, mutations at splice sites, and frameshift indels), (b) nonsynonymous mutations, and (c) LOF and nonsynonymous mutations (aggregated).
Burden testing (T1, T5, Variable Threshold, Madsen-Browning and SKAT) was implemented using ScoreSeq 27 and performed across all variants with MAF < 5%. All burden tests were adjusted for sex and the top ten PCs and performed on the QC-passing set of unrelated samples (1,169 cases and 608 controls).
Population stratification and externally sequenced controls. To assess the type I error in a burden testing framework, we simulated 100 different phenotypes for two scenarios: perfect matching and imperfect matching with a North-to-South gradient for the number of cases (keeping the case/control counts the same, Supplementary 
Study approval and informed consent
All participants gave written informed consent and the institutional review board of the University Medical Center Utrecht approved this study. Additional approval was obtained to access the Dutch Municipal Personal Records Database.
Results
Baseline characteristics and description of data
After quality control, 1,169 unrelated Dutch-ancestry cases and 608 ancestrallymatched controls were available for analysis. Their baseline characteristics are displayed in Table 1 and the distribution of cases and controls throughout The
Netherlands is displayed in Figure 2a . In total, 42,200,214 SNVs and indels passed quality control. The majority (69%) of these sequenced variants were rare (MAF < 0.001, < 3 allele observations in our dataset, Supplementary Figure 2) . In particular, the bulk of these rare variants were not observed in publicly available datasets of whole-genome sequencing data including the Genome of The
Netherlands project (GoNL release 5 from 28-10-2013, N = 498) and the 1000
Genomes Project (Phase 1 from 23-11-2010, N = 1,093). This observation reflects population-specific variants and the growing number of rare variants that will continue to be discovered as sequencing is performed in increasingly larger samples around the globe. As expected, most common variants (MAF > 1%) have been observed in these two datasets (97.5% in GoNL and 98% in the 1000 Genomes Project) reflecting global sharing of common variation.
Geographic clustering
The first and second principal components reflected the geographical distribution of cases and controls in detail (Figure 2b) . 
(a) Birthplaces of cases and controls for individuals born in The Netherlands. (b) The first two principal components reflect the geographical distribution of samples. Individuals are shaded by province of birth as shown in panel (a). The first principal component is strongly correlated with birthplace latitude (p = 8.4×10 -284 ) and the second principal component with longitude (p = 1.7×10 -107 ). (c-e) Relation between birthplace distance between pairs of individuals and shared IBD segments 1-2 cM (c), 2-7 cM (d) and 7-15 cM (e). Long IBD segments are, as expected, mostly shared by individuals born close to one another. PC: principal component, MAF: minor allele frequency, km: kilometer, cM: centimorgan.
Sharing of IBD segments showed strong geographical patterns throughout the
Netherlands. As was observed in a previous population genetics study in The
Netherlands there is a clear North-to-South gradient for sharing of shorter (and thus older) IBD segments (Supplementary Figure 4a) . We also confirmed the finding that people born in the Southern provinces shared more of these IBD segments with people from the Northern provinces than they share with people within their own province, reflecting the previously described complex migration patterns 14 
Association testing in ALS cases and controls
We found no variants reaching genome-wide significance (p = 5.0 × 10 -8 ) with ALS in our sample, as expected given the sample size. We looked up known associated single-variants, three of which showed nominal association to the trait (p < 0.05, Supplementary Table 1 
The implications of study design
We sought to evaluate how matching cases and control, thereby introducing finegrained population structure, influenced the burden testing type I error rate.
Therefore, we simulated phenotypes that (1) created perfectly geographically matched case-control sets and (2) introduced population structure between patients and controls (Supplementary Figure 1) . We subsequently ran simulations that did not correct for any covariates or those that included common-variant (MAF > 0.1%) principal components. Imperfect matching did not yield a markedly more stringent pvalue to maintain a study-wide type I error at 0.05 for all burden tests ( Figure 7a) . Removal of highly differentiated SNPs with a frequency difference > 5% across the two projects somewhat mitigated this separation (Supplementary Figure 7b) . As expected, single-variant testing between ALS cases and GoNL controls revealed excessive genomic inflation ( = 1.12). Similarly, burden testing comparing ALS cases and GoNL controls revealed a strongly inflated QQ plot and genomic inflation factor ( = 2.49), demonstrating the challenges of using externally sequenced controls to identify disease genes in a separately-sequenced set of cases and controls.
Discussion and future perspectives
Family-based and population-level genetic studies have revealed ALS as a complex disease with a distinct role for rarer genetic variation. Although numerous genetic variants have been identified as conferring ALS risk, the genetic basis in the vast majority of cases is not yet understood. Here, we have described the design and pilot analyses of a large-scale whole-genome sequencing study aimed at discovering new genetic risk factors and further elucidating the genetic basis of ALS.
Data sharing and open-access science
Data sharing and transparency in scientific research is advantageous for a host of reasons: it allows for analyses across large sets of samples, particularly for lowerprevalence diseases such as ALS; ensures rigorous experiments that can be reproduced by external groups; and allows for publicly-funded research to be made available to the public itself. Project MinE cannot publicly release individual-level genotype data due to consent. However, genotype frequency information and genic burden testing results are publicly available at the project's online browser (http://databrowser.projectmine.com/). This browser will be continuously updated as the project expands, and will provide more detailed data integration in future releases. To further enhance the transparency within the consortium itself and with external collaborators and researchers, the project has begun a GitHub repository, to share and maintain scripts and data processing pipelines.
The advantages of 'franchising'
Given the relatively low prevalence of ALS, international collaboration is crucial to assembling large samples. Thus far, the "franchise" design of our consortium has allowed us to rapidly expand to sixteen participating research groups globally. This joint effort has collected enough resources to sequence >7,000 samples, with more currently being collected. Ongoing analyses include case-control association testing, as well as association testing in age-of-onset, and survival time. Additionally, the available core clinical dataset, uniformly collected for all individuals included in Project MinE, will allow for a host of other discovery analyses.
Study design implications: data management, population architecture, and external controls
The pilot analyses, though small in sample size, yield several immediate and important conclusions. First, while genotype-called data (in VCF format) is easily handled by a high-performance compute cluster, whole-genome BAM files (approximately 80 gigabytes per genome) demand a compute infrastructure that can handle terabytes and even petabytes of data. This includes direct delivery of the genomes that are currently being sequenced via a direct high-speed connection between the sequencing provider and a computer cluster with a GRID architecture (SURFsara). Though some research institutions are already prepared for such a deluge of data, others will need to carefully consider compute infrastructure and the technical ramifications of assembling big data before embarking on large-scale sequencing analyses. Further, having all data stored in a single location enables analysis across the full dataset, including on BAM-level data.
Second, initial quality control of the data suggests that the high-depth sequencing and downstream genotype calling is yielding high-quality data, reflected in our ability to reconstruct, through principal component analysis and identity-by-descent analyses, demographic observations that have been made in separate large-scale sequencing efforts in the Dutch population. 14 Further, the population analyses performed here and in particular the birthplace analysis, highlights the sensitivity of genome-wide sequence data. The data must be carefully protected such that those who have donated DNA to enable disease research, will also remain anonymous (in accordance with the consent provided). 29 Third, the high-resolution geographical clustering of rare variants as observed in these analyses could pose challenges in finding rare variants that contribute to ALS [31] [32] [33] and indicate that obtaining a high-quality dataset requires calling genotypes from petabytes of raw data in a uniform way across the full set of samples. Additional developments in handling heterogeneous sequence data include association testing on read-level data to allow for externally sequenced controls. 34 Although these methods come with significant computational burden, similar approaches could be applied in Project MinE, in an effort to expand beyond the 22,500 samples sequenced initially by the project.
The future of Project MinE
With the veritable explosion in methods and approaches being developed for wholegenome sequence data analysis, Project MinE will seek to leverage new and powerful methods for uncovering ALS risk variants. Current plans include more sophisticated functional annotation techniques, such as unsupervised-learning approaches to discriminate between functionally relevant and benign variation in the genome 35, 36 ; implementing a linear mixed model approach to burden testing 30 ; a burden testing framework that will focus not only on genes but also on regulatory and other non-coding elements; and analyses that investigate both variation and methylation data. We have additionally established a pipeline to lift all our data to the newest genome build (hg38), which will likely yield better coverage of the genome in our samples. As the size of the data expands and additional collaborators join the effort, we will explore additional data structures that can facilitate transcontinental data analysis with minimal physical movement of data.
Finally, in addition to testing SNVs and indels, we will explore the role of more complex genetic variation such as structural variants and repeat expansions, which are known to play an important role in ALS susceptibility, yet have never been studied at genome-wide scale. With a global collaboration in place, a wealth of genetic variation being generated, and new methods for sequence data constantly in development, Project MinE will be the largest and most complete study of ALS genetics to date, poised to reveal novel risk loci, fine-map known disease genes, and shed light on the biological drivers of disease. 
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